Valeant Pharmaceuticals International Inc. said that Canadian regulators have approved its insomnia treatment Sublinox, and it expects to launch the product in the fourth quarter in Canada.
The Canadian drugmaker said Sublinox is a tablet that aims to provide short-term treatment and symptomatic relief of insomnia, which is characterized by difficulty falling asleep and frequent nighttime or early-morning awakenings.
Sublinox will be sold by a joint venture between Valeant and Meda AB.
Date: July 25, 2011
Source: Associated Press
Filed Under: Drug Discovery
